Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?

Area of Science:

• Urology
• Oncology
• Medical Statistics

Background:

• Accurate risk stratification is crucial for prostate cancer management.
• Clinical staging factors like D'Amico criteria and Roach formula are widely used.
• Assessing their predictive accuracy in modern patient cohorts is essential.

Purpose of the Study:

• To evaluate the predictive ability of clinical stage, D'Amico risk stratification, and Roach formula for pathologic outcomes in prostate cancer.
• To compare risk stratification using clinical versus pathologic T-stage.
• To compare predicted nodal risk with actual incidence.

Main Methods:

• Utilized Surveillance, Epidemiology, and End Results (SEER) data from 2004-2005.
• Included men with adenocarcinoma of the prostate and complete staging information.
• Stratified patients using D'Amico criteria and Roach formula, comparing clinical vs. pathologic T-stage.

Main Results:

• Pathologic staging frequently resulted in higher risk stratification than clinical criteria.
• A significant proportion of patients (34.7%) were up-staged from clinical to pathologic T-stage.
• The Roach formula tended to overestimate the actual incidence of pathologically positive lymph nodes.

Conclusions:

• Pathologic staging provides a more accurate risk assessment than clinical criteria for most prostate cancer patients.
• Nodal positivity is infrequent at diagnosis in the current era.
• The Roach formula may overestimate nodal positivity risk, suggesting limitations in its current application.